SecBot SecBot
PRESS-RELEASE ·Filed May 7, 2026

XENE

Xenon Pharmaceuticals Inc.
MIXED
Impact 6/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The positive X-TOLE2 data and near-term NDA submission are the primary catalysts, but the revenue decline and increased losses temper the bullish case. Traders should monitor enrollment updates for X-TOLE3 and X-ACKT studies, and any regulatory feedback ahead of the NDA filing.

DirectionMixed
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$56.44
T+0 close · May 7, 2026 · via day close
Latest settled
+13.41%
T+60 · $64.01
Vs SPY
+8.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $56.44entry
  2. T+1 · 6mo ago −1.17%α −1.40% · $55.78
  3. T+5 · 6mo ago −0.78%α −2.24% · $56.00
  4. T+20 · 5mo ago −8.35%α −8.37% · $51.73
  5. T+60 · 3mo ago +13.41%α +8.57% · $64.01
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M ($1.17/share) vs $65.0M ($0.83/share) in Q1 2025, with zero revenue compared to $7.5M a year ago. The miss is overshadowed by positive Phase 3 X-TOLE2 data for azetukalner in focal onset seizures, with an NDA submission expected in Q3 2026 and a strong cash position of $1.34B funding operations into 2029.

Key Financial Metrics

EPS
−$1.17
Revenue
$0.00
-100.0% YoY
Rating
miss

Key Facts

  • Phase 3 X-TOLE2 study met primary endpoint with placebo-adjusted median percent change in seizure frequency of -42.7% (25 mg dose), the highest ever observed in a pivotal FOS study.
  • NDA submission for azetukalner in focal onset seizures planned for Q3 2026.
  • Cash, cash equivalents and marketable securities of $1,339.6 million as of March 31, 2026, up from $586.0 million at year-end 2025.
  • Net loss increased to $102.3 million in Q1 2026 from $65.0 million in Q1 2025, driven by higher R&D spend and zero collaboration revenue.
  • Research and development expenses rose to $88.5 million from $61.2 million year-over-year.

Financial Impact

Net loss of $102.3M in Q1 2026, up from $65.0M in Q1 2025; revenue declined from $7.5M to $0.

revenuenetLossrdExpenses

Risk Factors

  • Regulatory delays or negative FDA review of the NDA for azetukalner.
  • Clinical trial setbacks in ongoing Phase 3 studies for MDD, BPD, or PGTCS.
  • Dilution risk from continued use of ATM or follow-on offerings despite strong cash position.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3290503

Track record

19 reports on XENE

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens Wed (10h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026